Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration

Inclusion criteria: * Written informed consent * History of grass pollen allergic rhinitis * Male and female between 18 years to 65 years * Positive skin prick test to grass pollen * Positive nasal provocation test Exclusion criteria: * Atopic eczema in history or permanent * Perennial allergic rhinitis * Symptoms of infectious disease with rhinitis in between the last 2 weeks * Surgical intervention in between the last 30 days * Pregnancy or nursing * History of HIV or AIDS * Mastocytosis (cutaneous or systemic) * Significant cardiovascular disease * Hypertension (blood pressure \> 160 / 95) * Significant pulmonary, renal and/or hepatic disease * Significant hematological disorder * Moderate or severe asthma * History of malignancy * History of neurological or psychatric disease * Autoimmune disease * Antihistamines with longed half-lives in the last week * Systemic or topical steroids for 5 days * Active infectious disease * Contraindicated medications: - immunosuppressive agents * Betablockers * ACE-inhibitors * Tricyclic antidepressants * Daily use of Beta-agonists or steroid inhalers * Participation in another clinical trial /study in between the last 60 days * Participation in another clinical trial / study at the moment